Jane Street
CRDL

Jane Street’s Cardiol Therapeutics CRDL Stock Holding History

Jane Street’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,800
Closed -$62.2K – 11753
2026
Q1 		$62.2K Buy
45,800
+2,800
+7% +$2.87K ﹤0.01% 10884
2025
Q4 		$41.1K Buy
+43,000
New +$45K ﹤0.01% 10560

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street's CRDL Position: Q2 2026 in Review

Jane Street reduced its Cardiol Therapeutics (CRDL) stake by 58% in Q2 2026, selling an estimated $93.1K and leaving 53,416 shares worth $56.1K. The position accounts for ﹤0.01% of the portfolio, ranked #10886.

Jane Street first reported a position in CRDL in Q3 2021 and has held it in 10 quarters since. The position peaked at $327K in Q3 2021. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Jane Street held 53,416 shares of Cardiol Therapeutics worth $56.1K as of Q2 2026.
  • Jane Street sold 73,541 Cardiol Therapeutics shares in Q2 2026, an estimated $93.1K.
  • Cardiol Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10886 holding.
  • Jane Street first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • Jane Street's Cardiol Therapeutics position peaked at $327K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.